·¬ΗΡΚΣΖ΅

Meeting Coverage

IKCS

International Kidney Cancer Symposium

'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma

Potential standard of care after current therapies, but key obstacles remain in the way

IKCS over a photo of Omni Nashville Hotel, Nashville, Tennessee

Latest IKCS Meeting Coverage

Targeting New Pathways to Improve Outcomes in Renal Cell Carcinoma

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

November 14, 2023
No Boost in Outcomes for Clear Cell RCC With Higher Belzutifan Dose

A quarter of patients responded whether at the recommended or higher dose

November 13, 2023
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma

Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients

November 11, 2023
Role of Cytoreductive Nephrectomy Unclear for Dedifferentiated Kidney Cancer

Thirteen-month survival gain falls short of statistical significance in observational study

November 10, 2022
Immune Stimulator May Enhance Targeted Therapy's Activity in Metastatic RCC

Numerical advantage in median survival, response rate, durability with dendritic-cell agent

November 9, 2022
Immunotherapy Doublet Shows Promise for Nonsurgical Control of Small Kidney Cancers

Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors

November 7, 2022
Probiotic May Rev Up Response to Immunotherapy in Advanced Kidney Cancer

Dramatic slowing of disease progression, prolonged responses with microbiome modulator

November 6, 2022
Metastatic Renal Cell Carcinoma: Watch for Brain Mets

Present in roughly 5% of patients, survival worse in patients with larger or more lesions

November 18, 2019
Kidney Cancer Patients Take to Twitter for Support, Info

Social media platform may be useful for trial recruitment, researchers say

November 5, 2017